A Phase 1 interventional study of midazolam and metformin in Healthy Study Participants, sponsored by UCB BIOSCIENCES, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to assess the single-dose pharmacokinetics (PK) of 3 probe drugs (midazolam, bupropion, and metformin) before and after repeat doses of ZX008
UCB BIOSCIENCES, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants will receive a single dose of the cocktail of probe drugs at pre-specified timepoints followed by a wash out period. The same study participants will then receive repeated oral doses of fenfluramine HCl (ZX008) and a single dose of the cocktail of probe drugs at pre-specified time points during this Treatment Period.
Drug: midazolam · Drug: metformin · Drug: bupropion · Drug: fenfluramine HCl
Study participants will receive a pre specified single oral dose of probe drug midazolam on Day 1 and Day 22 of the study
Study participants will receive a pre-specified single oral dose of probe drug metformin on Day 1 and Day 22 of the study
Study participants will receive a pre-specified single oral dose of probe drug bupropion on Day 1 and Day 22 of the study
Study participants will receive pre-specified repeated oral doses of fenfluramine HCl (ZX008) from Day 6 to 26 during the study
Also known as: Fintepla, ZX0008
Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State
Cmax is the maximum observed plasma concentration of Midazolam alone and in combination with ZX008 at steady state.
Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Maximum Concentration (Cmax) of Metformin Alone and in Combination With ZX008 at Steady State
Cmax is the maximum observed plasma concentration of Metformin alone and in combination with ZX008 at steady state.
Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Maximum Concentration (Cmax) of Bupropion Alone and in Combination With ZX008 at Steady State
Cmax is the maximum observed plasma concentration of Bupropion alone and in combination with ZX008 at steady state.
Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Area Under the Curve From 0 to Infinity (AUC) of Midazolam Alone and in Combination With ZX008 at Steady State
AUC is area under the plasma concentration-time curve from time 0 to infinity of Midazolam alone and in combination with ZX008 at steady state.
Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Area Under the Curve From 0 to Infinity (AUC) of Metformin Alone and in Combination With ZX008 at Steady State
AUC is area under the plasma concentration-time curve from time 0 to infinity of Metformin alone and in combination with ZX008 at steady state.
Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Area Under the Curve From 0 to Infinity (AUC) of Bupropion Alone and in Combination With ZX008 at Steady State
AUC is area under the plasma concentration-time curve from time 0 to infinity of Bupropion alone and in combination with ZX008 at steady state.
Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Midazolam Alone and in Combination With ZX008 at Steady State
AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Midazolam alone and in combination with ZX008 at steady state.
Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Metformin Alone and in Combination With ZX008 at Steady State
AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Metformin alone and in combination with ZX008 at steady state.
Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Bupropion Alone and in Combination With ZX008 at Steady State
AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Bupropion alone and in combination with ZX008 at steady state.
Time frame: Day 1 (Treatment Period 1) and Day 22 (Treatment Period 2): Predose, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10,12, 24, 36, 48, 72, and 96 hours Postdose
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A treatment-emergent adverse events was defined as any AE with a start date and time on or after the first dose of any study drug or any unresolved event already present before treatment administration that worsens infrequency or intensity following exposure to any of the study drugs. The percentage of participants data was rounded to one decimal place. SFU: Safety Follow-Up.
Time frame: From Baseline (Day 1) to the End of Safety Follow-Up (up to 116 days)
The study started to enroll participants in December 2024 and concluded in June 2025.
| Milestone | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period) |
|---|---|---|
| Started | 22 | 0 |
| Completed | 22 | 0 |
| Not completed | 0 | 0 |
| Milestone | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period) |
|---|---|---|
| Started | 0 | 22 |
| Completed | 0 | 22 |
| Not completed | 0 | 0 |
Cmax is the maximum observed plasma concentration of Midazolam alone and in combination with ZX008 at steady state.
| nanograms per milliliter (ng/mL) | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) |
|---|---|---|
| Maximum Concentration (Cmax) of Midazolam Alone and in Combination With ZX008 at Steady State | 10.44 ± 31.6 | 8.203 ± 40.6 |
Cmax is the maximum observed plasma concentration of Metformin alone and in combination with ZX008 at steady state.
| ng/mL | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) |
|---|---|---|
| Maximum Concentration (Cmax) of Metformin Alone and in Combination With ZX008 at Steady State | 943.6 ± 17.4 | 959.8 ± 26.0 |
Cmax is the maximum observed plasma concentration of Bupropion alone and in combination with ZX008 at steady state.
| ng/mL | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) |
|---|---|---|
| Maximum Concentration (Cmax) of Bupropion Alone and in Combination With ZX008 at Steady State | 76.11 ± 39.6 | 68.50 ± 39.1 |
AUC is area under the plasma concentration-time curve from time 0 to infinity of Midazolam alone and in combination with ZX008 at steady state.
| hour*nanograms per milliliter (hr*ng/mL) | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) |
|---|---|---|
| Area Under the Curve From 0 to Infinity (AUC) of Midazolam Alone and in Combination With ZX008 at Steady State | 24.84 ± 46.2 | 19.08 ± 47.5 |
AUC is area under the plasma concentration-time curve from time 0 to infinity of Metformin alone and in combination with ZX008 at steady state.
| hr*ng/mL | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) |
|---|---|---|
| Area Under the Curve From 0 to Infinity (AUC) of Metformin Alone and in Combination With ZX008 at Steady State | 6381 ± 22.0 | 6482 ± 23.9 |
AUC is area under the plasma concentration-time curve from time 0 to infinity of Bupropion alone and in combination with ZX008 at steady state.
| hr*ng/mL | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) |
|---|---|---|
| Area Under the Curve From 0 to Infinity (AUC) of Bupropion Alone and in Combination With ZX008 at Steady State | 407.7 ± 27.0 | 378.0 ± 33.0 |
AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Midazolam alone and in combination with ZX008 at steady state.
| hr*ng/mL | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) |
|---|---|---|
| Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Midazolam Alone and in Combination With ZX008 at Steady State | 24.09 ± 47.1 | 18.40 ± 49.0 |
AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Metformin alone and in combination with ZX008 at steady state.
| hr*ng/mL | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) |
|---|---|---|
| Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Metformin Alone and in Combination With ZX008 at Steady State | 6365 ± 21.4 | 6448 ± 23.3 |
AUC(0-t) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration of Bupropion alone and in combination with ZX008 at steady state.
| hr*ng/mL | 3-probe Drug Cocktail Alone (Treatment Period 1) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2) |
|---|---|---|
| Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration AUC(0-t) of Bupropion Alone and in Combination With ZX008 at Steady State | 344.8 ± 40.0 | 351.0 ± 33.6 |
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A treatment-emergent adverse events was defined as any AE with a start date and time on or after the first dose of any study drug or any unresolved event already present before treatment administration that worsens infrequency or intensity following exposure to any of the study drugs. The percentage of participants data was rounded to one decimal place. SFU: Safety Follow-Up.
| percentage of participants | 3-probe Drug Cocktail Alone (Treatment Period 1: D1-D5) | ZX008 15 mg BID Alone (Treatment Period 2: D6-D21) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2: D22-SFU) |
|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 13.6 | 50.0 | 22.7 |
Collected over From Baseline (Day 1) to the End of Safety Follow-Up (up to 116 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3-probe Drug Cocktail Alone (Treatment Period 1: D1-D5) | 0/22 (0%) | 0/22 (0%) | 1/22 (4.5%) |
| ZX008 15 mg BID Alone (Treatment Period 2: D6-D21) | 0/22 (0%) | 0/22 (0%) | 7/22 (31.8%) |
| ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2: D22-SFU) | 0/22 (0%) | 0/22 (0%) | 2/22 (9.1%) |
| Event | 3-probe Drug Cocktail Alone (Treatment Period 1: D1-D5) | ZX008 15 mg BID Alone (Treatment Period 2: D6-D21) | ZX008 15 mg BID + 3-probe Drug Cocktail (Treatment Period 2: D22-SFU) |
|---|---|---|---|
| FatigueGeneral disorders | 0/22 | 4/22 | 0/22 |
| HeadacheNervous system disorders | 0/22 | 3/22 | 0/22 |
| DiarrhoeaGastrointestinal disorders | 1/22 | 0/22 | 2/22 |
Baseline Characteristics refer to the Safety Set which consisted of all study participants who had received at least 1 dose of any of the study treatments.
| Age, Continuous(years) | All Treated Participants |
|---|---|
| Mean | 37.4 ± 8.5 |
| Age, Customized(Participants) | All Treated Participants |
|---|---|
| 18 - <65 years | 22 |
| 65 - <85 years | 0 |
| >= 85 years | 0 |
| Sex: Female, Male(Participants) | All Treated Participants |
|---|---|
| Female | 10 |
| Male | 12 |
| Race/Ethnicity, Customized(Participants) | All Treated Participants |
|---|---|
| Asian | 1 |
| Black or African American | 13 |
| White | 8 |
| Race/Ethnicity, Customized(Participants) | All Treated Participants |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.
Ran from Dec 2024 to primary completion in Jun 2025, 6 months.
Results were first posted in Jul 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenfluramine